Europe Genetic Testing Market – Diagnostics Trends & Forecast 2026–2034

Europe Genetic Testing Market Size and Forecast 2026-2034

Europe Genetic Testing Market is expected to reach US$ 14.61 billion by 2034 from US$ 7.25 billion in 2025, with a CAGR of 8.1% from 2026 to 2034. The Europe genetic testing market is projected to experience robust growth during the forecast period, driven by expanding precision medicine, technological innovation, increasing awareness of inherited disorders, and wider adoption of genomic healthcare solutions.

Europe Genetic Testing Industry Overview

The Europe genetic testing market is witnessing continuous expansion as genomic technologies become increasingly integrated into modern healthcare, disease prevention, and personalized medicine. Healthcare providers throughout the region are utilizing genetic testing to improve disease diagnosis, assess inherited health risks, guide treatment selection, and support reproductive health decisions. Applications now extend beyond rare genetic disorders to include oncology, cardiovascular diseases, neurological conditions, pharmacogenomics, prenatal screening, and population health initiatives. Hospitals, specialized diagnostic laboratories, research institutes, and private healthcare providers are steadily expanding their genomic testing capabilities to meet growing clinical demand. The increasing emphasis on preventive healthcare and personalized treatment strategies has further strengthened the role of genetic testing as a critical component of patient-centered healthcare across Europe.

Technological advancement continues to reshape the European genetic testing landscape through the introduction of highly accurate, faster, and more comprehensive testing platforms. Next-generation sequencing, whole genome sequencing, exome sequencing, polymerase chain reaction technologies, chromosomal microarrays, and bioinformatics tools have significantly enhanced the ability to detect genetic variations associated with numerous medical conditions. Artificial intelligence and advanced data analytics are also improving interpretation of complex genomic information, enabling clinicians to make more informed treatment decisions. Continuous innovation has reduced laboratory turnaround times while increasing testing efficiency and scalability. In addition, expanding collaborations between biotechnology companies, academic research institutions, pharmaceutical manufacturers, and healthcare organizations are accelerating the development of novel diagnostic applications that support precision medicine and translational research throughout Europe.

The European genetic testing industry is supported by strong healthcare infrastructure, extensive biomedical research, and growing public awareness regarding the benefits of genomic medicine. Governments and healthcare systems continue promoting genomic research initiatives, rare disease programs, and national screening strategies that encourage wider utilization of genetic testing technologies. Regulatory frameworks emphasizing quality assurance, laboratory accreditation, and patient safety contribute to maintaining high standards across diagnostic services. Growing integration of companion diagnostics into targeted therapy development has further expanded commercial opportunities for diagnostic manufacturers. Meanwhile, increasing demand for non-invasive prenatal testing, hereditary cancer screening, and pharmacogenomic testing continues broadening the clinical scope of genetic diagnostics. As precision healthcare becomes increasingly central to medical practice, Europe is expected to remain one of the world's leading markets for genetic testing, supported by continuous scientific innovation, expanding clinical adoption, and sustained investment in genomic research and healthcare modernization.

Growth Drivers for the Europe Genetic Testing Market

Extension of Population and Newborn Genomic Screening Initiatives in EU Member States

Supported by EUR 25 million in government grants, Belgium's BabyDetect program examines babies for over 200 illnesses and provides results in two weeks, identifying curable metabolic and immunodeficiency abnormalities before biochemical panels. In order to identify actionable variations that may benefit from early interventions like enzyme replacement or dietary changes, the UK's Newborn Genomes Programme is sequencing 200,000 infants. In order to harmonize genomic data pipelines across seven member states, these pilots make use of Screen4Care, a EUR 15 million Horizon Europe project. Early detection of uncommon diseases has increased by 35%, according to data, confirming program scalability and increasing demand for variant-interpretation tools and high-throughput sequencers.

Demand for BRCA and multigene tests is being driven by an increase in the prevalence of hereditary cancers

According to updated European oncology guidelines, germline testing is recommended for all patients under 50 who have breast or ovarian cancer, increasing the test-eligible group fourfold from 2022. Multigene cancer panels are priced between GBP 399 and GBP 1,400 (USD 499–1,750) by private labs in the UK, making them a cost-effective addition to single-gene tests that are paid by the government. Family cascade testing, which finds actionable mutations in 12–15% of relatives compared to 5–8% for BRCA-only screening, will receive EUR 50 million from France's 2025 National Cancer Plan. As a result, demand drives the growth of tele-oncology and counseling services, and labs incorporate reflex RNA-based fusion tests to optimize useful results from the same biopsy sample.

Growing European Healthcare Systems' Use of NGS-Based Comprehensive Panels

NGS tumor and rare-disease panels are currently reimbursed by national health systems, increasing diagnostic yields above 40% as opposed to 25% for sequential single-gene assays. The UK's NHS provides free BRCA screening to Jewish women over 30, indicating a shift in policy toward preventive genomics, while Germany's Molecular Tumor Board network offers thorough genomic profiling for advanced tumors. Laboratory capacity upgrades, increased demand for reagents, and investments in cloud-based bioinformatics that directly interface with electronic clinical records are all prompted by reimbursement clarity. In response, device manufacturers introduced CE-IVD designated comprehensive tests that include gene-fusion profiling, microsatellite instability, and tumor mutation burden into a single test run.

Challenges in the Europe Genetic Testing Market

Test Uptake Is Limited by the Lack of Certified Genetic Counselors

Hospitals must use "mainstreaming" models that train cardiologists and oncologists to offer limited counselling because Europe needs 4,000 more trained genetic counsellors to handle current caseloads, but universities only produce 200 of them each year. The UK relies on tele-genetics and group therapy sessions because there are only 400 counsellors for every 67 million citizens, which is far less than the required ratio of 1 per 100,000. Due to severe shortages, Baltic and Balkan patients receive virtual consultations from cross-border clinics in Berlin and Vienna. Physician referrals are discouraged by lengthy wait times for pre- and post-test counselling, especially for complex prenatal or oncology panels that require sophisticated risk communication.

Ethical, Legal, and Data Privacy Concerns

The increasing use of genetic testing has introduced important ethical and regulatory challenges throughout Europe. Genetic information is highly sensitive and requires robust privacy protection, secure data management, and transparent patient consent procedures. Healthcare providers and diagnostic laboratories must comply with strict regulatory standards governing the collection, storage, interpretation, and sharing of genomic information. Concerns regarding potential misuse of genetic data, discrimination, and confidentiality continue influencing public perception of genetic testing services. Differences in national regulations across European countries may also create operational complexity for companies offering cross-border genomic services. Successfully maintaining public trust while ensuring responsible management of genetic information remains a critical challenge affecting the long-term development of the European genetic testing market.

United Kingdom Genetic Testing Market

The United Kingdom represents one of Europe's most advanced genetic testing markets, supported by its strong biomedical research ecosystem, established genomic medicine programs, and sophisticated healthcare infrastructure. Hospitals, academic medical centers, and specialized diagnostic laboratories increasingly integrate genetic testing into routine clinical practice for oncology, inherited disorders, reproductive health, and pharmacogenomics. Ongoing collaboration between research institutions, biotechnology companies, and healthcare providers encourages continuous innovation in genomic diagnostics and personalized medicine. The growing adoption of digital healthcare technologies and laboratory automation further improves testing efficiency and clinical decision-making. Expanding awareness of preventive healthcare and individualized treatment strategies continues driving demand for comprehensive genetic testing services, reinforcing the United Kingdom's leading position within the European genomic diagnostics landscape.

The genetic testing market is significantly shaped by government funding and efforts, especially in the UK. The government has launched a number of initiatives to encourage research and development in this area after realizing the potential of genetic testing to improve public health outcomes. The UK government has recently committed more than £200 million to genomics initiatives, indicating an increase in funding for genetic research. The market for genetic testing grows as a result of these investments, which also promote innovation and cooperation between public health organizations and private businesses. As these programs develop further, they will probably make the environment more conducive to genetic testing and encourage its incorporation into routine medical procedures.

Germany Genetic Testing Market

Germany maintains a prominent position within Europe's genetic testing market through its advanced healthcare system, strong biotechnology sector, and extensive investment in medical research. Diagnostic laboratories are steadily expanding genomic testing capabilities to support personalized medicine, hereditary disease screening, cancer diagnostics, and precision therapeutics. Healthcare providers increasingly utilize molecular diagnostics and advanced sequencing technologies to improve diagnostic accuracy and patient management. Strong collaboration between universities, clinical research organizations, pharmaceutical companies, and biotechnology firms continues fostering innovation throughout the genomic medicine ecosystem. The country's emphasis on scientific excellence, laboratory quality standards, and technological modernization supports the adoption of sophisticated diagnostic solutions. These factors continue strengthening Germany's role as a major contributor to Europe's genetic testing industry.

France Genetic Testing Market

France continues to strengthen its genetic testing market through sustained investment in genomic research, clinical innovation, and personalized healthcare initiatives. Hospitals and specialized diagnostic centers increasingly adopt advanced molecular testing technologies to improve disease diagnosis, inherited disorder detection, reproductive medicine, and precision oncology applications. National efforts to modernize healthcare infrastructure and integrate genomic medicine into clinical practice have encouraged broader adoption of advanced laboratory solutions. Academic institutions and biotechnology companies actively collaborate to accelerate the development of innovative diagnostic technologies and genomic research programs. Increasing public awareness regarding preventive healthcare and genetic counseling further supports market expansion. France's commitment to scientific advancement and patient-centered healthcare continues creating favorable opportunities for long-term growth in genetic diagnostics.

Italy Genetic Testing Market

Italy's genetic testing market is experiencing progressive development as healthcare providers expand access to advanced genomic diagnostics across hospitals, research institutions, and specialized laboratories. Clinical applications continue broadening beyond rare disease diagnosis to include oncology, prenatal screening, cardiovascular genetics, and pharmacogenomics. Medical institutions are investing in modern sequencing technologies, laboratory automation, and integrated bioinformatics platforms to improve diagnostic precision and operational efficiency. Collaborative initiatives involving universities, biotechnology companies, and healthcare organizations contribute to ongoing innovation within the country's genomic medicine sector. Increasing awareness of inherited disease prevention and personalized treatment planning further supports demand for comprehensive genetic testing services. These developments position Italy as an increasingly important participant in Europe's evolving genetic testing market.

Recent Developments in Europe Genetic Testing Market

• In June 2025: Illumina completed a USD 350 million acquisition of SomaLogic to combine high-plex proteomics with panels for hereditary diseases and cancer in European laboratories.

Research Methodology of the Europe Genetic Testing Market

Step 1: Market Definition and Scope

The Europe Genetic Testing Market was first defined according to the types of genetic tests, technologies, applications, end users, and countries covered by the study.

The scope included molecular genetic testing, chromosomal testing, cytogenetic testing, next-generation sequencing (NGS), whole-genome sequencing, whole-exome sequencing, PCR-based testing, microarray testing, carrier screening, prenatal testing, newborn screening, hereditary disease testing, oncology genetic testing, pharmacogenomic testing, and genetic predisposition testing.

The market definition also distinguished between clinical genetic testing, direct-to-consumer testing, and research-use testing, depending on the study scope.

Step 2: Estimate the Number of Genetic Tests Performed

The estimation was initiated by determining the number of genetic tests conducted across European countries.

The calculation considered:

• Number of clinical genetic tests
• Hereditary disease tests
• Oncology tests
• Prenatal and newborn tests
• Carrier screening
• Pharmacogenomic tests, etc.

Country-level test volumes were estimated using national healthcare statistics, laboratory databases, hospital activity, genetic-testing registries, reimbursement records, academic studies, laboratory networks, and company disclosures.

Step 3: Apply Average Selling Price per Genetic Test

After estimating test volumes, an average selling price (ASP) was established for each major genetic-testing category.

The ASP was differentiated according to:

• Testing technology
• Clinical application
• Complexity of analysis
• Sample type
• Sequencing depth
• Laboratory type
• Reimbursement status
• Country, etc.

The calculation was:

Genetic Testing Market Value = Number of Tests × Average Selling Price per Test

Step 4: Build the Bottom-Up Market Estimate

The bottom-up approach was used as the primary estimation method.

The market was calculated country by country and then aggregated:

Europe Genetic Testing Market = Σ (Country Genetic Testing Volume × Country Average Selling Price)

Each country's estimate was further divided by:

• Test type
• Technology
• Application
• End user
• Distribution channel

This approach helped capture differences in testing penetration, healthcare systems, reimbursement, pricing, and clinical adoption between European countries.

Step 5: Technology-Based Estimation

The market was subsequently segmented according to technology.

The main categories included:

• NGS
• PCR
• Microarray
• Sanger sequencing
• Cytogenetics, etc.

For each technology, the market was calculated using:

Number of Tests × Average Technology-Specific ASP

NGS-based testing was treated separately because sequencing-based assays generally had different equipment, reagent, laboratory, and interpretation economics from conventional genetic testing.

Step 6: Laboratory Revenue and Company-Level Validation

The bottom-up estimate was cross-checked against revenues generated by major genetic-testing laboratories and diagnostic companies.

The analysis considered:

• Genetic-testing revenue
• Molecular diagnostics revenue
• Laboratory testing volumes
• Test menus
• Number of testing centers
• Genetic-testing partnerships
• New assay launches
• Sequencing capacity
• Geographic presence, etc.

Where companies reported broader diagnostics revenues, the genetic-testing component was estimated using their product portfolios, testing volumes, genetic-testing services, and country exposure.

Step 7: Healthcare and Reimbursement Validation

Healthcare reimbursement information was used to validate the estimated number and value of clinical genetic tests.

The analysis considered:

• National reimbursement schedules
• Insurance coverage
• Public healthcare expenditure
• Reimbursement rates
• Number of reimbursed tests
• Hospital laboratory activity
• Genetic counselling pathways
• Public versus private testing

This approach was important because genetic-testing prices could differ substantially between reimbursed clinical testing, private-pay testing, research testing, and direct-to-consumer testing.

Step 8: Top-Down Validation

A top-down approach was then used as an independent validation method.

The calculation was structured as:

European Diagnostics Market × Genetic Testing Share = Europe Genetic Testing Market

A second top-down calculation could have been based on:

Molecular Diagnostics Market × Genetic Testing Component

The genetic-testing share was derived from laboratory revenues, test volumes, company portfolios, healthcare statistics, and country-level research, rather than being assigned arbitrarily.

Step 9: Supply-Side and Trade Validation

Import and export information for relevant genetic-testing equipment, reagents, kits, and laboratory products was used as an additional validation layer.

The apparent supply could have been calculated as:

Domestic Production + Imports − Exports = Apparent Domestic Supply

Trade classifications were reviewed carefully because genetic-testing products could have been included within broader categories covering diagnostic reagents, laboratory equipment, sequencing equipment, molecular-testing kits, and other IVD products.

Therefore, trade data were used primarily as a supporting validation source, rather than as the sole basis for the market calculation.

Step 10: Third Validation and Market Triangulation

The final market estimate was triangulated using three independent approaches:

A. Bottom-Up Approach

Genetic testing volume × average selling price.

B. Top-Down Approach

European diagnostics or molecular-diagnostics market × genetic-testing share.

C. Supply/Company Approach

Genetic-testing company revenues + laboratory revenues + test volumes + supply/trade information.

The estimates were compared and discrepancies were investigated based on:

• Differences in market definitions
• Clinical versus consumer testing
• Reimbursement versus private pricing
• Laboratory revenue recognition
• Test volume reporting
• Reagent-only versus complete testing revenue
• Equipment versus testing-service revenue
• Cross-border testing
• Public and private laboratories
• Double counting between molecular diagnostics and genetic testing

The final market value was established after reconciling these differences rather than simply averaging the three estimates.

Step 11: Country-Level Market Estimation

The European market was calculated separately for individual countries before being aggregated into the regional market.

The country model incorporated:

• Population
• Number of births
• Cancer incidence
• Genetic disease prevalence
• Genetic-testing penetration
• Healthcare expenditure
• Laboratory infrastructure
• Reimbursement policies
• Number of genetic laboratories
• Testing prices
• Adoption of NGS and precision medicine

The country-level estimates were then aggregated:

Germany + UK + France + Italy + Spain + Netherlands + Switzerland + Belgium + Nordics + Rest of Europe = Europe Genetic Testing Market

This approach reduced the risk of applying a single European testing rate or ASP across countries with substantially different healthcare systems.

Step 12: Historical Market Estimation

Historical market values were estimated using historical genetic-testing volumes, ASPs, reimbursement rates, laboratory revenues, technology adoption, and country-level healthcare data.

Historical prices were applied to the corresponding years rather than applying current test prices retrospectively.

The model also incorporated changes in:

• NGS adoption
• Genetic disease testing
• Oncology testing
• Prenatal testing
• Pharmacogenomics
• Direct-to-consumer testing
• Reimbursement coverage
• Laboratory capacity

Step 13: Market Forecasting

The future Europe Genetic Testing Market was forecast using expected growth in testing volumes, technology adoption, average testing prices, clinical applications, and geographic penetration.

The basic forecasting formula was:

Future Market = Future Genetic Testing Volume × Future Average Selling Price

Testing volume forecasts incorporated:

• Aging population
• Increasing genetic disease diagnosis
• Growth in precision medicine
• Expansion of oncology testing
• Increasing NGS adoption
• Prenatal and newborn screening
• Pharmacogenomics
• Genetic counselling
• Greater awareness of inherited disorders
• Expansion of personalized healthcare
• Increasing availability of laboratory testing

The forecast also considered regulatory and market-access developments because the IVDR framework had strengthened requirements for IVD performance, conformity assessment, and post-market surveillance.

Core Market Formula

Europe Genetic Testing Market = Σ [Country Genetic Testing Volume × Country Average Selling Price]

The bottom-up test-volume approach was used as the foundation, while laboratory revenues, company disclosures, reimbursement data, healthcare statistics, regulatory information, and supply-side data were used as independent validation layers. This methodology provided a structured basis for estimating the historical, current, and forecast Europe Genetic Testing Market.

Market Segments:

Type

• Predictive Testing
• Carrier Testing
• Prenatal and Newborn Testing
• Diagnostic Testing
• Pharmacogenomic Testing
• Nutrigenomic Testing
• Others

Product

• Consumables
• Equipments
• Software & Services

Technology

• PCR
• DNA Sequencing
• Microarrays
• Others

Disease

• Cancer
• Genetic Diseases
• Cardiovascular Diseases
• Rare Diseases
• Infectious Diseases
• Others

End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Country 

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbott Laboratories
• Danaher Corporation (Cepheid Inc.)
• Illumina Inc.
• BioRad Laboratories Inc.
• F Hoffmann-La Roche AG
• Diasorin
• Revvity Inc.
• Thermo Fisher Scientific Inc.

Report Details: